An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease

NCT ID: NCT02293915

Last Updated: 2018-10-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 818 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-04-01
• Study Completion Date: 2018-09-28

Brief Summary

The primary purpose of this study is to determine the efficacy and safety of Sodium Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.

Conditions

Mild to Moderate Alzheimer Disease; Cognitive Impairment

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

sodium oligo-mannurarate 900mg

Group Type: EXPERIMENTAL

Sodium oligo-mannurarate 900mg

Intervention Type: DRUG

sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

simulant of sodium oligo-mannurarate capsule

Interventions

Sodium oligo-mannurarate 900mg

sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks

Intervention Type: DRUG

Placebo

simulant of sodium oligo-mannurarate capsule

Intervention Type: DRUG

Other Intervention Names

GV-971

Eligibility Criteria

Inclusion Criteria

1. Aged 50-85 years (inclusive), no gender limitation;

2. Female subjects should be postmenopausal women (menopause >24 weeks), surgically sterilized women or women of child bearing age who agree to take effective contraceptive measures during the trial. Women of child bearing age and women less than 24 weeks from menopause must undergo urine pregnancy test in screening period and result must be negative;

3. Subjects have received education in primary school and above and are able to complete protocol specified cognitive ability test and other tests;

4. Impaired memory for at least 12 months, with a tendency of progressive aggravation;

5. Meet diagnostic criteria of probable AD according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (1984);

6. Patients with mild to moderate disease, i.e. 11 ≤total MMSE score ≤26 (for subjects with primary school education, 11 ≤total MMSE score ≤22);

7. Total Hachinski Ischemia Scale (HIS) score ≤4 ;

8. Total Hamilton Depression Scale/17-item (HAMD) score ≤10;

9. In screening, cranial MRI plain scan and oblique coronal hippocampus scan must be performed, lacunar infarction lesions with a diameter larger than 2 cm ≤2, without lacunar infarction lesion in vital sites, such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, cortex and other subcortical gray matter nuclei; MRI shows highest possibility of Alzheimer's disease (medial temporal lobe atrophy visual rating scale MTA grade ≥2);

10. Neurological examination shows no significant sign;

11. Subjects should have stable, reliable caregivers, or at least have frequent contact with caregivers (at least 4 days every week, at least 2 h every day), and caregivers will help patients in participation in this study. Caregivers must accompany subjects to participate in study visits and have sufficient interaction and communication with subjects, so as to provide valuable information on NPI, ADCS-ADL, CIBIC-plus scales.

12. Before implementation of any protocol related procedure or examination, subjects must sign the written informed consent form. If subjects can not sign due to limited cognition, legal guardians should sign on behalf of subjects and meanwhile, legal guardians should also sign the informed consent form.

Exclusion Criteria

1. Participate in another clinical trial within 30 days prior to initiation of this study;

2. Pregnant or nursing women;

3. Dementia due to other causes: vascular dementia, central nervous system infection (e.g. AIDS, syphilis), Creutzfeldt-Jakob disease, Huntington's chorea, Parkinson's disease, dementia with Lewy bodies, traumatic dementia, other physical and chemical factors (e.g. drug poisoning, alcoholism, carbon monoxide poisoning), significant physical illness (e.g. hepatic encephalopathy, pulmonary encephalopathy), intracranial occupying lesion (e.g. subdural hematoma, brain tumor), endocrine disorders (e.g. thyroid disease, parathyroid disease) and dementia caused by vitamin or other factors;

4. Previous nervous system disorders (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy);

5. Abnormal laboratory values: liver function (ALT, AST) > 1.5 times of upper limit of normal, Cr > 1.5 times of upper limit of normal, white blood cell count, platelet, hemoglobin below the lower limit of normal, blood glucose >1.5 times of upper limit of normal;

6. In screening, systolic blood pressure ≥160 mmHg or <90 mmHg, or diastolic blood pressure ≥100 mmHg or <60 mmHg;

7. Unstable or severe cardiac, pulmonary, hepatic, renal or hematopoietic disease (including unstable angina, uncontrolled asthma, active gastric bleeding and cancer), after 10 min rest, resting heart rate <55 bpm;

8. Visual or hearing disorder, preventing completion of neuropsychological test and scale evaluation;

9. In screening, MRI examination shows significant focal lesions, more than 2 lacunar infarction lesions with a diameter >2 cm, lacunar infarction lesions in vital sites, such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, cortex and other subcortical gray matter nuclei; Fazekas scale for white matter lesions at ≥ grade 3;

10. Alcohol abuse or drug abuse;

11. Patients with psychosis, including severe depression;

12. Patients who are using drugs for Alzheimer's disease which can not be stopped;

13. Use of heparin, Propylene Glycol Mannurate Sulfate or Alginric Sodium Diester within 3 weeks prior to screening;

14. Inability to take trial drugs according to prescription, previous non-compliance with prescription or possibility of non-compliance with study treatment in the trial;

15. Investigators consider subjects can not complete this study;

16. Subjects in the phase II trial of the study drug;

17. Subjects are investigators participating in this study or their direct relatives, staff of Quintiles (Shanghai) or Shanghai Greenvalley Pharmaceutical Co., Ltd. or their direct relatives.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Greenvalley Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing

Beijing, Beijing Municipality, China

Chongqing

Chongqing, Chongqing Municipality, China

Fujian

Fuzhou, Fujian, China

Guangzhou

Guangzhou, Guangdong, China

Wuhan

Wuhan, Hubei, China

Changsha

Changsha, Hunan, China

Nanjing

Nanjing, Jiangsu, China

Suzhou

Suzhou, Jiangsu, China

Yangzhou

Yangzhou, Jiangsu, China

Jinan

Jinan, Shandong, China

Shanghai

Shanghai, Shanghai Municipality, China

Xi'an

Xi’an, Shanxi, China

Sichuan

Chengdu, Sichuan, China

Tianjin

Tianjin, Tianjin Municipality, China

Hangzhou

Hangzhou, Zhejiang, China

Wenzhou

Wenzhou, Zhejiang, China

Countries

China

References

Ferrari C, Sorbi S. The complexity of Alzheimer's disease: an evolving puzzle. Physiol Rev. 2021 Jul 1;101(3):1047-1081. doi: 10.1152/physrev.00015.2020. Epub 2021 Jan 21.

Reference Type: DERIVED

PMID: 33475022 (View on PubMed)

Other Identifiers

971-III

Identifier Type: -

Identifier Source: org_study_id